Market closed

Aldeyra Therapeutics/ALDX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Aldeyra Therapeutics

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Ticker

ALDX
Trading on

Industry

Biotechnology

Employees

10

ALDX Metrics

BasicAdvanced
$319M
Market cap
-
P/E ratio
-$0.64
EPS
1.45
Beta
-
Dividend rate
$319M
1.45
$6.18
$1.46
444K
4.553
2.911
0.141
15.905
-21.22%
-19.11%
-33.19%
3.25
3.25
-10.367
-28.00%
-15.27%

What the Analysts think about ALDX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Aldeyra Therapeutics stock.

ALDX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ALDX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy ALDX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Aldeyra Therapeutics stock?

Aldeyra Therapeutics (ALDX) has a market cap of $319M as of October 26, 2024.

What is the P/E ratio for Aldeyra Therapeutics stock?

The price to earnings (P/E) ratio for Aldeyra Therapeutics (ALDX) stock is 0 as of October 26, 2024.

Does Aldeyra Therapeutics stock pay dividends?

No, Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders as of October 26, 2024.

When is the next Aldeyra Therapeutics dividend payment date?

Aldeyra Therapeutics (ALDX) stock does not pay dividends to its shareholders.

What is the beta indicator for Aldeyra Therapeutics?

Aldeyra Therapeutics (ALDX) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.